quinine sulfate + ciprofloxacin

Quinine sulfate + ciprofloxacin is an oral combination of two small-molecule drugs: quinine sulfate, an antimalarial agent primarily used for treatment of malaria, and ciprofloxacin, a fluoroquinolone antibiotic mainly used to treat a variety of bacterial infections. The combination is not standard or widely marketed under a unique brand, but it has been studied experimentally for use in treating drug-resistant malaria. Mechanistically, quinine acts as a blood schizonticide by interfering with the parasite's ability to digest hemoglobin in red blood cells, leading to parasite death. Ciprofloxacin targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes critical for bacterial DNA replication and repair, displaying bactericidal activity. Ciprofloxacin has also shown some in vitro and in vivo anti-malarial activity, supporting investigation of this combination in resistant malaria cases. Pharmacokinetic studies reveal a significant interaction: ciprofloxacin inhibits cytochrome P450 3A4 (CYP3A4), the enzyme responsible for the metabolism of quinine, resulting in increased plasma quinine levels and decreased formation of its major metabolite, 3-hydroxyquinine. Because this increases the risk of adverse quinine effects (such as QT prolongation and other toxicities), close monitoring and quinine dose adjustment are necessary when the combination is used.